Debt-to-equity of Compass Therapeutics, Inc. from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Compass Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • Compass Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 15%, a 173% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Compass Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 15% +9.6% +173% 30 Sep 2025
Q2 2025 15% +9.9% +190% 30 Jun 2025
Q1 2025 11% +5.6% +107% 31 Mar 2025
Q4 2024 7% +0.54% +8.4% 31 Dec 2024
Q3 2024 5.5% -2% -26% 30 Sep 2024
Q2 2024 5.2% -3.1% -37% 30 Jun 2024
Q1 2024 5.2% -4% -43% 31 Mar 2024
Q4 2023 6.4% -3.4% -35% 31 Dec 2023
Q3 2023 7.5% -2.3% -23% 30 Sep 2023
Q2 2023 8.3% -3.5% -29% 30 Jun 2023
Q1 2023 9.3% -5.6% -38% 31 Mar 2023
Q4 2022 9.9% -13% -57% 31 Dec 2022
Q3 2022 9.8% -30% -75% 30 Sep 2022
Q2 2022 12% -23% -66% 30 Jun 2022
Q1 2022 15% -18% -55% 31 Mar 2022
Q4 2021 23% -249% -92% 31 Dec 2021
Q3 2021 39% +424% 30 Sep 2021
Q2 2021 35% +56% 30 Jun 2021
Q1 2021 33% +39% 31 Mar 2021
Q4 2020 271% +278% 31 Dec 2020
Q3 2020 -385% -385% -475975% 30 Sep 2020
Q2 2020 -21% -21% -21161% 30 Jun 2020
Q1 2020 -5.9% -5.8% -4209% 31 Mar 2020
Q4 2019 -6.4% -6.2% -2569% 31 Dec 2019
Q3 2019 -0.08% 30 Sep 2019
Q2 2019 -0.1% 30 Jun 2019
Q1 2019 -0.14% 31 Mar 2019
Q4 2018 -0.24% 31 Dec 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.